- Home
- AMWD vs XNCR Comparison
AMWD vs XNCR Comparison
Compare AMWD & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMWD | XNCR |
|---|---|---|
| Founded | 1980 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Forest Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 872.8M | 881.9M |
| IPO Year | 1995 | 2013 |
Fundamental Metrics
Financial Performance| Metric | AMWD | XNCR |
|---|---|---|
| Price | $35.58 | $11.38 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $59.50 | $22.33 |
| AVG Volume (30 Days) | 203.9K | ★ 668.1K |
| Earning Date | 05-28-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,709,585,000.00 | $125,576,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.80 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $34.31 | $6.92 |
| 52 Week High | $72.16 | $18.69 |
Technical Indicators
Market Signals| Indicator | AMWD | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 32.09 | 39.72 |
| Support Level | N/A | $11.02 |
| Resistance Level | $42.58 | $13.28 |
| Average True Range (ATR) | 2.00 | 0.81 |
| MACD | -0.73 | -0.13 |
| Stochastic Oscillator | 10.22 | 14.21 |
Price Performance
Historical ComparisonAbout AMWD American Woodmark Corporation
American Woodmark Corp manufactures and distributes cabinets and vanities for the remodeling and new home construction markets. It offers several products that fall into product lines including kitchen cabinetry, bath cabinetry, office cabinetry, home organization, and hardware. The products are sold under the brand names American Woodmark, Timberlake, Shenandoah Cabinetry, and Waypoint Living Spaces among others.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.